GlassScriptPhysician profile
Eniki A Mack
NPI 1730307927
$6,138.64
in general payments reported to CMS, 2019-2025
39 companies · $1,551 in 2025
The $1,551 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $919 · 2020: $102 · 2021: $108 · 2022: $755 · 2023: $1,681 · 2024: $1,024 · 2025: $1,551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,213 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,213.48 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $1,088.10 | 2019-2025 | |
| Novo Nordisk INC | $1,039.25 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $449.72 | 2019-2025 | Tepezza, Evenity, Prolia |
| Insulet Corporation | $354.21 | 2019-2024 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $307.12 | 2022-2024 | |
| Tandem Diabetes Care, INC. | $261.45 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Xeris Pharmaceuticals, INC. | $248.67 | 2020-2025 | Gvoke Hypopen |
| Lilly USA, LLC | $223.34 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $205.94 | 2021-2025 | Jardiance, Synjardy |
| Beta Bionics, INC. | $175.74 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Astrazeneca Pharmaceuticals LP | $164.60 | 2022-2023 | Farxiga |
| Dexcom, INC. | $142.97 | 2023-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $142.39 | 2021-2025 | Freestyle Libre 3 |
| Medtronic, INC. | $140.04 | 2023-2024 | Minimed 780g |
| Merck Sharp & Dohme LLC | $105.59 | 2019 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sequel Med Tech, LLC | $103.30 | 2025 | Twiist |
| Medtronic Minimed, INC. | $98.76 | 2019 | |
| Mannkind Corporation | $87.48 | 2025 | |
| Corcept Therapeutics | $83.06 | 2024-2025 | Korlym |
| Genzyme Corporation | $72.79 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $64.11 | 2025 | Orencia |
| Ucb, INC. | $63.81 | 2023-2025 | Bimzelx, Cimzia |
| Actelion Pharmaceuticals US, INC. | $58.14 | 2023-2025 | Opsumit, Uptravi |
| Cequr Corporation | $49.50 | 2025 | Cequr Simplicity |
| Janssen Biotech, INC. | $45.96 | 2024 | Tremfya |
| Aurinia Pharma U.S., INC. | $38.19 | 2023-2024 | Lupkynis |
| Intuity Medical INC | $38.12 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Alexion Pharmaceuticals, INC. | $36.75 | 2024-2025 | Strensiq |
| Apellis Pharmaceuticals, INC. | $33.94 | 2025 | Empaveli |
| Radius Health, INC. | $32.09 | 2023 | Tymlos |
| Madrigal Pharmaceuticals | $25.63 | 2025 | Rezdiffra |
| Averitas Pharma INC. | $22.08 | 2025 | Qutenza |
| Organon LLC | $21.35 | 2025 | |
| Exact Sciences Corporation | $21.28 | 2024 | Cologuard Collection Kit |
| Amphastar Pharmaceuticals, INC. | $20.99 | 2025 | |
| Harmony Biosciences LLC | $20.35 | 2021 | |
| Calliditas Therapeutics US INC. | $19.64 | 2023 | Tarpeyo |
| Embecta Corp. | $17.54 | 2024 | |
| Valeritas, INC. | $14.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eniki Mack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.